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ABSTRACT
Objectives: The Functional Assessment of Cancer Therapy–Kidney
Symptom Index—Disease-Related Symptoms (FKSI-DRS) was developed
to assess patients’ kidney-cancer-related symptoms. The Rasch rating
scale, a one-parameter logistic item response model, may enhance FKSI-
DRS interpretation and validate its measurement properties.
Methods: We applied the Rasch model to FKSI-DRS data from a random-
ized phase 3 trial in which ﬁrst-line sunitinib therapy showed superiority
to interferon-alfa in patients with metastatic renal cell carcinoma. Of 750
enrolled patients, 668 patients completed the questionnaire on cycle 1, day
28 and were evaluated in the current study. The nine FKSI-DRS items were
analyzed to enhance interpretation of the summary score by using an item
characteristic curve that related score to probability of reporting speciﬁc
symptoms.
Results: The Rasch model ﬁtted the FKSI-DRS well: 8 of 9 items had
acceptable inﬁt and outﬁt statistics (<1.5, >0.5); item difﬁculty
spanned a wide range (-3.23 to 1.64 logits); and the ﬁve response catego-
ries performed adequately. The item characteristic curve offered enhanced
interpretation of FKSI-DRS: For example, an FKSI-DRS score of 27 (mean
baseline score for total sample) indicated a 47% chance of reporting “no”
to “lack of energy,” although a two-point difference between sunitinib and
interferon-alfa, averaged across all assessments (29 vs. 27), corresponded
to sunitinib achieving a 28% increase (13% absolute difference) in the
probability of reporting “no” to “lack of energy” (60% vs. 47%).
Conclusions: Data suggest that the FKSI-DRS is an adequate measure of
symptom status in patients with metastatic renal cell carcinoma. The
Rasch model supports its validation and enhances its interpretation.
Keywords: FKSI-DRS, mRCC, Rasch model, symptom status, validation
study.
Introduction
The Functional Assessment of Cancer Therapy–Kidney Symptom
Index—Disease Related Symptoms (FKSI-DRS) was developed to
measure the impact of disease-related symptoms in patients with
advanced kidney cancer [1]. It was derived from the 15-item
Functional Assessment of Cancer Therapy–Kidney Symptom
Index (FKSI-15) [2], an instrument that captures the most impor-
tant disease- and treatment-related symptoms and concerns of
patients with kidney cancer. The FKSI-DRS includes a subset of
nine items from its parent instrument, the FKSI-15, but excludes
the treatment-related symptom items, focusing solely on disease-
related symptom items [1]. A recent validation study using clas-
sical test theory (CTT) methods has shown the FKSI-DRS to have
sound psychometric properties [1].
CTT is a body of psychometric theory used to assess and
improve the measurement properties of an instrument and has
been the most inﬂuencial theory in the area of psychometrics,
because the methods are relatively simple [3]. Nevertheless, the
CTT methods present a major limitation in that the measurement
statistics, such as item difﬁculty (percentage of correct responses),
item discrimination (item-total correlation), and reliability, are
dependent on the respondents to whom the instrument is admin-
istered [4]. During the last decades, a group of new statistical
models, the item response theory (IRT), has been developed and
has become an important complement to CTT in instrument
development, evaluation, and reﬁnement. Within the framework
of IRT, item characteristics are not dependent on the sample of
respondents and are assumed to be invariant across different
populations and among divergent groups of respondents [4–7].
The IRT models also offer additional advantages over CTT.
Unlike CTT, which focuses primarily on assessing summed scale
scores, the IRT models analyze individual component items of an
instrument by a set of properties that describe the relationship of
the item with the underlying construct measured by the instru-
ment, as well as how well individual items ﬁt with respect to the
underlying construct [4–7]. Such analysis allows researchers to
identify the items that can most accurately measure the underly-
ing construct. In addition, while the CTT methods provide a
single estimate of reliability for different levels of the underlying
construct, the IRT models can assess the accuracy of an instru-
ment across varying spans of the underlying construct [4–7]. As
a result of their associated advantages, IRT models have been
used widely to develop and reﬁne instruments [8], assess group
differences in item or scale function [9], link and calibrate scales
from different instruments that measure the same underlying
construct [10], develop computerized adaptive testing [4,5], and
enhance instrument interpretation by translating the meaning of
a scale score into the probability of an item response [11].
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The FKSI-DRS has been used recently in a randomized phase
3 trial of sunitinib malate (SUTENT®; Pﬁzer Inc., New York, NY,
USA) versus interferon-alfa (IFN-a) as ﬁrst-line systemic therapy
for patients with metastatic renal cell carcinoma (mRCC) [12].
This trial revealed a statistically signiﬁcant improvement in FKSI-
DRS with the use of sunitinib compared with IFN-a. In the
current study, we applied the Rasch model—an IRT method—to
FKSI-DRS data from this phase 3 trial. Our objectives were to
enhance interpretation of the FKSI-DRS and to provide further
validation of its psychometric properties.
Methods
Study Sample
In the phase 3 trial of sunitinib versus IFN-a on which the
current study was based [12], 750 patients with mRCC who were
at least 18 years old had not previously received systemic therapy
and showed evidence of measurable disease and an Eastern
Cooperative Oncology Group (ECOG) performance status of 0
or 1 [12] and were randomized to receive sunitinib or IFN-a in
repeated 6 weekly cycles. The trial was conducted at 39 centers
in the United States, 10 centers in Canada, 8 centers in Poland, 8
centers in Russia, 7 centers in Australia, 6 centers in France, 6
centers in Italy, 5 centers in Spain, 5 centers in the United
Kingdom, 4 centers in Germany, and 3 centers in Brazil. Sunitinib
was administered as an oral capsule at a dosage of 50 mg daily
for 4 weeks followed by 2 weeks off treatment (4/2 schedule).
IFN-a, the active comparator, was administered as a subcutane-
ous injection on 3 nonconsecutive days per week. Patients treated
with IFN-a received 3 million units (MU) per dose during the
ﬁrst week, 6 MU per dose during the second week, and 9 MU per
dose thereafter. Dose modiﬁcations were permitted for toxicity
management with both treatments. In addition to other eligibility
criteria, patients had to be willing and able to complete assess-
ments on patient-reported outcomes [12].
The data in the current study were collected on day 28 of
treatment cycle 1 for 668 patients participating in this phase 3
trial for whom data were available. We selected this assessment
time point for two reasons. First, we sought to evaluate the
performance of the FKSI-DRS during a treatment period when
sufﬁcient variation in (nonmissing) item responses was expected.
Second, among all the treatment cycles, day 28 of cycle 1 pro-
vided the largest sample size. Nevertheless, we also conducted the
analysis on patients at baseline and on day 28 of treatment cycles
2 to 4, when most patients continued to complete the FKSI-DRS.
The FKSI-DRS
The FKSI-DRS is a patient-reported instrument that consists of
nine items [1]. It measures whether the patient has experienced
any of the following nine kidney cancer-related symptoms within
the last 7 days: lack of energy, fatigue, weight loss, pain, bone
pain, shortness of breath, cough, fever, or blood in the urine [1].
Each item is scored by using the following ﬁve response catego-
ries: 0, not at all; 1, a little bit; 2, somewhat; 3, quite a bit; and
4, very much [1]. In this study, we reverse-coded all items so that
a value of 4 was associated with fewer symptoms and a value of
0 with more symptoms (4, not at all; 3, a little bit; 2, somewhat;
1, quite a bit; 0, very much). Responses to all FKSI-DRS items
were summed to generate a summary symptom score ranging
from 0 to 36, with higher scores indicating improved (more
favorable) symptom status.
Selection of the Rasch Model
There are several available IRT models. In this study, we applied
a rating scale extension of the Rasch model, one of the simpler
and more commonly used IRT models [4–7,13]. The Rasch
model was originally developed for dichotomous (two-choice)
items by Georg Rasch [14]. In the Rasch model, the probability
of a speciﬁc response to a speciﬁc test question (item) can be
modeled as a logistic function of the difference between the
person’s ability (usually measured by using test questions/items)
and the difﬁculty of the items [13]. If a person’s ability is high and
an item is easy, the person has a high probability of answering the
item correctly. In CTTmethod, it may be difﬁcult to determine
the extent to which each of the test items adequately measures
underlying personal ability. Nevertheless, the Rasch model
allows the contribution of each test item to be evaluated more
accurately. Thus, if a patient shows better symptom status mea-
sured by FKSI-DRS (low severity or frequency of the symptom in
the FKSI-DRS) and a symptom is rare, the patient has a high
probability of answering “no” to this symptom item in the FKSI-
DRS. Conversely, if a patient shows worse symptom status (high
severity or frequency of the symptoms in the FKSI-DRS) and a
symptom is common, the patient has a low probability of
answering “no” to this symptom item.
The Rasch model addresses only item difﬁculty and assumes
equal discriminating ability across all items. It is also known as
the one-parameter logistic model, with the one parameter corre-
sponding to the difﬁculty of an item. In contrast, other types of
IRT model, such as the two-parameter logistic model, can esti-
mate a discrimination parameter for each instrument item [4–7].
For instruments that have more than two response categories,
like the FKSI-DRS, there are two major types of Rasch model
that ﬁt the response data: the rating scale model and the partial
credit model [13]. In the rating scale model, a set of items shares
the same rating scale structure, and respondents are presented
with the same response categories for each item [15]. In contrast,
each item in the partial credit model has its own rating scale
structure, and response categories may vary between items [16].
Because the items of the FKSI-DRS all share the same rating
scale, the rating scale model was selected for this study [15,17],
and its goodness-of-ﬁt to the data was assessed. Using the Rasch
rating scale model for the ﬁrst threshold, for example, the prob-
ability of a patient n choosing a response category of 1 (“quite a
bit”) over a category of 0 (“very much”) on an item i (e.g., “I
have pain”) can be computed by using the following fomula
[13]:
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where Bn is the nth patient’s symptom status, Di is the difﬁculty
of responding to item i with the highest category (4 = “not at
all”), and F1 represents the threshold between categories 1 and 0.
Estimates of item difﬁculty (Di) and patient symptom status (Bn)
were expressed on a scale of log odd ratios or logits. The average
logit is arbitrarily set at 0, with positive logits indicating higher-
than-average estimates and negative logits lower-than-average
estimates. A threshold is the location on the symptom status scale
at which a patient has a 50/50 chance of choosing a higher
category than the current one (e.g., category 1 rather than cat-
egory 0). In the FKSI-DRS, each item has ﬁve ordinal response
categories, as noted previously. Consequently, for the ﬁve catego-
ries, there are four thresholds corresponding to the locations on
the scale at which patients can choose higher over lower
responses (1 over 0, 2 over 1, 3 over 2, and 4 over 3). Because all
items share the same rating scale structure in the Rasch model,
the value of a speciﬁc threshold (e.g., F1) has the same value
across all items. All analyses of the Rasch rating scale model were
conducted in WINSTEPS (Winsteps, Chicago, IL) [18].
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Validation of the FKSI-DRS
To validate the FKSI-DRS, we assessed whether all FKSI-DRS
items contribute adequately to the measurement of symptom
status. The Rasch model assumes a unidimensional latent (unob-
served) construct or concept [4,13]. Thus, if the responses to an
item successfully ﬁt the Rasch model, it provides evidence that
this item adequately measures the underlying concept.
Mean square ﬁt statistics were used to test the model ﬁt for all
of the FKSI-DRS items. Each item was calculated as an average of
squared differences between the observed and expected responses
from the Rasch model [13]. Two types of mean square ﬁt statis-
tics (inﬁt and outﬁt statistics) were assessed. The inﬁt statistic is
a weighted estimate that gives more weight to responses close to
modeled estimates of an item [13]. The inﬁt statistic is usually
inﬂuenced by response patterns, is hard to diagnose and remedy,
and presents a threat to internal validity. In contrast, the outﬁt
statistic is an unweighted estimate that is more likely to be
inﬂuenced by unexpected responses [13], is easier to diagnose,
and presents less of a threat to measurement. Both inﬁt and outﬁt
statistics have an expected value of 1 and an accepted range of ﬁt
of 0.5 to 1.5 [18].
In addition to assessing item ﬁt, we also examined the FKSI-
DRS response categories to determine whether the categories
performed sufﬁciently well to create an interpretable measure.
Our assessment proceeded in two steps. First, we investigated
average symptom estimates for patients who chose a particular
category. In the case of the FKSI-DRS, average symptom esti-
mates are expected to increase (more favorable symptom status)
as the category increases (toward less symptomology or a lower
magnitude of symptoms). The monotonicity (a monotonic
sequence being one in which successive values move in the same
direction) of average symptom estimates was based on the
assumption that patients with more favorable symptom status
should endorse higher categories (e.g., “not at all”), whereas
those with less favorable symptom status should endorse lower
categories (e.g., “very much”) [13]. Categories showing a viola-
tion of this pattern were considered disordered and suspect [13].
Second, we assessed thresholds and category ﬁt. Thresholds
should increase monotonically because patients with symptom
estimates falling into higher thresholds should be more likely to
endorse higher categories. A lack of threshold monotonicity was
considered disordered and suspect [13]. Category ﬁt statistics
provide additional criteria for assessing the functioning of
response categories. For each response category, mean square
inﬁt and outﬁt statistics were calculated. Categories with inﬁt or
outﬁt statistics of >1.5 or <0.5 were considered to be misﬁts [18].
The Rasch model is not intended to provide direct informa-
tion about the discriminating ability of an item—i.e., the ability
of an item to differentiate between patients with different
symptom status levels. To determine the discriminating ability of
the FKSI-DRS items, we conducted corrected and uncorrected
item-total correlations. An item with a corrected or uncorrected
item-total correlation of <0.3 was considered to have poor dis-
criminating ability [19]. Analysis of the item-total correlation
was performed by using SAS (SAS Institute, Cary, NC) [20].
Interpretation of the FKSI-DRS
A content-based approach was used to interpret and enhance the
meaning of the FKSI-DRS summary score. A content-based inter-
pretation of a health status measure uses a representative item
internal to the measure itself, along with its response categories,
to understand the meaning of different scores on that measure
[11,21–23]. Therefore, each FKSI-DRS item in our study was
analyzed by relating the FKSI-DRS summary scale score to the
probability of responding “not at all” to this symptom item using
an item characteristic curve (ICC) from the Rasch model analy-
sis. To simplify the ICC, we combined the four response catego-
ries (“very much,” “quite a bit,” “somewhat,” and “a little bit”)
into a single category (“a little bit–very much”). We then plotted
the relationship between the summary scale score and the prob-
ability of a category response in the ICC using just two response
categories (“not at all” vs. “a little bit–very much”). ICCs were
originally designed to relate the probability of an item response
to the difference between symptom estimate and item difﬁculty
on a logit scale.
We converted the logit scale into the corresponding original
scale of measurement ranging from 0 to 36 and arbitrarily set the
item difﬁculty as 0. Symptoms scores on the logit scale were
converted directly to expected scores on the original scale of
measurement (18), ranging from 0 (highest symptoms) to 36
(lowest symptoms). The conversion from logits to the original
scale of measurement is part of the WINSTEPS program and has
been applied and published elsewhere [11]. After the conversion,
the probability of responding “not at all” for a particular item
becomes directly related to the symptom estimate (the FKSI-DRS
summary score) on its original scale of measurement. As the nine
items of the FKSI-DRS would yield nine separate graphs, we
plotted ICCs for all nine items on the same graph to provide a
simple yet comprehensive visualization of the data.
Results
Characteristics of the Study Subjects
A total of 750 patients were enrolled in the phase 3 trial, of
whom 668 patients completed the questionnaire on day 28 of
cycle 1. Among these 668 patients, more than two-thirds were
male (72.6%), and the average age was 60.1 years (SD = 9.7).
The majority of the patients were white (92.7%), and 62.3% had
an ECOG performance status of 0, indicating that they were fully
active and able to perform all predisease activities without
restrictions.
Validation of the FKSI-DRS
Our analysis of the questionnaires completed at baseline and on
day 28 of treatment cycles 2 to 4 (when most of the enrolled
patients still gave completed responses) gave results consistent
with those reported on day 28 of cycle 1 (data not shown).
Therefore, only results from day 28 of cycle 1 are reported here.
Table 1 summarizes the results for the corrected item-total
correlation (excluding the item of interest from the total score)
and the uncorrected item-total correlation (including the item of
Table 1 Corrected and uncorrected item-total correlation for
FKSI-DRS
Items (N = 644)
Uncorrected
item-total
correlation
Corrected
item-total
correlation
I have a lack of energy. 0.74 0.61
I have pain. 0.66 0.50
I am losing weight. 0.52 0.37
I have bone pain. 0.56 0.40
I feel fatigue. 0.77 0.65
I have been short of breath. 0.66 0.51
I have been coughing. 0.50 0.34
I am bothered by fevers. 0.49 0.35
I have had blood in my urine. 0.16* 0.10*
*Item-total correlation <0.3.
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interest from the total score) for each of the nine FKSI-DRS
items. Except for the item “I have had blood in my urine,” all
items had corrected item-total correlations (range: 0.35–0.65)
and uncorrected item-total correlations (range: 0.49–0.77) of
>0.3, suggesting acceptable discriminating ability. The items “I
feel fatigue” and “I have a lack of energy” showed the highest
corrected and uncorrected item-total correlations. These two
items exhibited the greatest ability to discriminate between
patients with kidney cancer with different symptom status levels.
Table 2 summarizes the model ﬁt statistics, item difﬁculty,
and category frequency for each of the nine FKSI-DRS items. As
shown in the table, all of the FKSI-DRS items exhibited accept-
able outﬁt mean squares (0.5–1.5). Similarly, except for the item
“I have had blood in my urine,” all items had acceptable inﬁt
mean squares. Item difﬁculty spanned a relatively wide range
(-3.23 to 1.64 logits) in which the item “I have a lack of energy”
was the least likely (most difﬁcult) to obtain a response of “not at
all.” The item “I have had blood in my urine” was the most likely
(least difﬁcult) to obtain a response of “not at all.” Consistent
with the item difﬁculty ﬁndings, only 9% of patients reported
“not at all” to the item “I have a lack of energy,” whereas 98%
of patients reported “not at all” to the item “I have had blood in
my urine” (Table 2).
When analyzing each rating scale category (Table 3), we
found that all items (except for the item “I have had blood in my
urine”) showed expected monotonic increases in average
symptom estimates (in logits) as the rating scales moved from
lower to higher categories (from “very much” to “not at all”).
Average symptom estimates were obtained from all patients who
chose a speciﬁc category of an item. For all items, except for the
item “I have had blood in my urine,” patients with higher
symptom estimates (more favorable symptom status) were more
likely to endorse higher response categories (e.g., “not at all”),
whereas patients with lower symptom estimates (less favorable
symptom status) were more likely to endorse lower response
categories (e.g., “very much”).
Information on category threshold and ﬁt statistics is sum-
marized in Table 4. Because the Rasch rating scale model was
used in this study, all items shared the same set of category
thresholds. As shown in Table 4, the thresholds for all response
categories increased monotonically and in the expected direction.
Patients whose symptom estimates fell into higher thresholds
(e.g., 1.21 logits) were more likely to endorse higher categories
(“not at all” or “a little bit”), whereas patients whose symptom
estimates fell into lower thresholds (e.g., -1.35 logits) were more
likely to endorse lower response categories (“quite a bit” or
“very much”). The inﬁt mean-square statistics for all ﬁve
response categories were within the accepted range (0.5–1.5).
The outﬁt mean-square statistics for all categories, except for
“very much,” were also within the accepted range (Table 4).
Interpretation of the FKSI-DRS
Figure 1 presents ICC data for the probability of reporting “not at
all” to each of the FKSI-DRS items, given an estimate of a patient’s
FKSI-DRS summary score. For example, a patient with a score of
16 on the FKSI-DRS summary scale was expected to have a <5%
chance of reporting “not at all” to the item “I have a lack of
energy.” This patient also had an approximately 30% chance of
reporting “not at all” to “I have pain” and nearly a 100% chance
of reporting “not at all” to “I have had blood in my urine.” In
contrast, a patient with a score of 28 was expected to have an
approximately 50% chance of reporting “not at all” to “I have a
lack of energy” and almost a 90% chance of reporting “not at all”
to “I have pain,” but the same likelihood (100%) as the patient
who scored 16 of reporting “not at all” to “I have had blood inmy
urine.”
Differences in the FKSI-DRS summary score between treat-
ment groups can also be ascertained from Figure 1. For a two-
point difference between sunitinib and IFN-a, averaged across all
postrandomization assessments (29.4 vs. 27.4), the difference in
probability of reporting “not at all” to “I have a lack of energy”
Table 2 Inﬁt and outﬁt statistics for each FKSI-DRS item and frequency of response categories
FKSI-DRS items (sample size, n)
Item
difﬁculty
Inﬁt mean
square
Outﬁt mean
square
Category frequency
Not at all
(%)
A little bit
(%)
Somewhat
(%)
Quite a bit
(%)
Very much
(%)
I have a lack of energy. (n = 666) 1.64 0.66 0.67 9 25 32 23 11
I have pain. (n = 661) 0.6 1.01 1.00 36 30 20 11 3
I am losing weight. (n = 660) -0.05 1.17 1.25 51 31 13 4 2
I have bone pain. (n = 659) -0.07 1.35 1.18 58 20 14 6 2
I feel fatigue. (n = 662) 1.52 0.58 0.58 11 28 31 21 9
I have been short of breath. (n = 663) 0.28 1.01 0.92 46 27 18 8 3
I have been coughing. (n = 664) -0.04 1.24 1.29 51 31 12 4 2
I am bothered by fevers. (n = 663) -0.63 1.35 1.25 71 16 8 3 1
I have had blood in my urine. (n = 662) -3.23 2.35* 1.41 98 1 1 0 0
*Indicates misﬁt.
Table 3 Average measures of each response category for FKSI-DRS items
FKSI-DRS items (sample size, n) Very much Quite a bit Somewhat A little bit Not at all
I have a lack of energy. (n = 666) 0.44 1.07 1.51 2.34 3.51
I have pain. (n = 661) 0.39 0.61 1.12 1.73 2.43
I am losing weight. (n = 660) -0.2 0.68 1.01 1.51 2.12
I have bone pain. (n = 659) 0.2 0.45 0.99 1.58 2.09
I feel fatigue. (n = 662) 0.4 0.93 1.46 2.28 3.46
I have been short of breath. (n = 663) 0.05 0.52 0.97 1.59 2.31
I have been coughing. (n = 664) 0.15 0.5 1.07 1.54 2.09
I am bothered by fevers. (n = 663) -0.28 0.36 0.87 1.35 1.96
I have had blood in my urine. (n = 662) 0.2 -0.28* 0.85 0.96 1.71
*Indicates a disordered category.
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was 13% (60% vs. 47%). This ﬁnding suggests that sunitinib
treatment, compared with IFN-a, resulted in a 28% (= 13% /
47%) increase in the probability of reporting “no” to “a lack of
energy.” Similarly, the probability of reporting “not at all” to “I
feel fatigue” increased from 50% with IFN-a to 63% with suni-
tinib, giving a 26% (= 13% / 50%) increase in the probability of
reporting “no” to “I feel fatigue” for sunitinib. For the same
two-point difference, the probability of reporting “not at all” to
“I have pain” differed by only 4% (95% vs. 91%), and there was
no difference in the probability of reporting “not at all” to “I
have had blood in my urine” (100% vs. 100%).
Figure 1 also offers a visual depiction of the relative frequency
of each FKSI-DRS symptom item and provides information on
the extent to which “not at all” is reported for each item. For
example, the curves for the items “I have a lack of energy” and
“I feel fatigue” are concentrated to the right of the horizontal
axis, where higher FKSI-DRS summary scores are located. These
two items were the least likely (most difﬁcult) to obtain a “not at
all” response and therefore represented the most common symp-
toms. In contrast, the curve for the item “I have had blood in my
urine” is concentrated to the left of the horizontal axis, where
lower FKSI-DRS summary scores are located. This item was the
most likely (least difﬁcult) to obtain a “not at all” response and
therefore represented the rarest symptom.
Discussion
The last 10 years have witnessed increased demands for patient-
reported outcomes in cancer research and for validated instru-
ments to support them. Consequently, the need for enhanced
interpretation of patient-reported outcome measures has also
increased. In this study, we used the Rasch model to validate and
support the interpretation of the FKSI-DRS. Findings from this
study suggest that the FKSI-DRS items are, in general, adequate
and appropriate for the measurement of underlying symptom
status in patients with mRCC. The Rasch rating scale model
proved useful for enhancing the interpretation of the FKSI-DRS
and for supporting its validation.
The FKSI-DRS has been validated previously by using classi-
cal test theory [1]. Results from these validation studies indicated
that the FKSI-DRS had acceptable internal consistency reliability,
and showed good evidence of convergent, divergent, and known-
group validity. The FKSI-DRS also demonstrated responsiveness
to clinical change and was able to differentiate between patients
with different treatment responses. The current Rasch model
analysis supported these independent studies by further analyz-
ing the performance of each item and response category of the
FKSI-DRS. The Rasch model assessment indicated that all FKSI-
DRS items, except the item “I have had blood in my urine,” had
acceptable inﬁt and outﬁt statistics, suggesting that, in general,
the FKSI-DRS items are consistent with the measurement of a
single underlying symptom construct.
The Rasch model assessment also revealed adequate perfor-
mance of the ﬁve FKSI-DRS response categories by showing that:
1) average symptom estimate for each response category increased
monotonically and in the expected direction as response catego-
ries moved from lower to higher categories; 2) the thresholds of
adjacent response categories increased monotonically and in the
expected direction; and 3) each of the ﬁve response categories
showed acceptable inﬁt statistics, and almost all categories had
acceptable outﬁt statistics.
In addition to instrument validation, the Rasch model analy-
sis provides a useful method for understanding the meaning of
FKSI-DRS scores. The FKSI-DRS has been used in clinical studies
to assess the impacts of drug treatments on patient-reported
symptoms. Use of this summary scale is likely to increase in the
future because more emphasis is placed on patient-reported out-
comes in oncology studies. Nevertheless, conveying FKSI-DRS
ﬁndings to patients, physicians, and other health-care providers
is a major challenge because many are not familiar with this
summary scale. For example, what does a score of 16 or a
two-point change on the FKSI-DRS mean? To address questions
like these, we used the Rasch model to relate speciﬁc FKSI-DRS
Table 4 Threshold estimates and model ﬁt for response categories of
the FKSI-DRS
FKSI-DRS
response categories Threshold
Inﬁt mean
square
Outﬁt mean
square
Not at all 1.21 0.99 1.00
A little bit 0.57 0.86 0.79
Somewhat -0.43 0.98 1.17
Quite a bit -1.35 0.98 1.01
Very much None 1.23 1.9*
*Indicates a misﬁt category.
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items.
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scores to the probability of not having a particular kidney-
cancer-related symptom. Thus, a score of 16 on the FKSI-DRS
summary scale would indicate a 5% chance of reporting “not at
all” to the item “I have a lack of energy,” a 30% chance of
reporting “not at all” to “I have pain,” and almost a 100%
chance of reporting “not at all” to “I have had blood in my
urine.” A two-point increase on the FKSI-DRS from 27 to 29,
associated with the postbaseline use of sunitinib compared with
IFN-a, would correspond to sunitinib resulting in an increase of
28% and 26% in the probability of reporting “not at all,”
respectively, to “I have a lack of energy” and “I feel fatigue.”
Because patients, physicians, and health-care providers are
usually more familiar with symptoms like “lack of energy” or
“fatigue,” translating a FKSI-DRS score into the probability of
these particular symptoms occurring will help them to achieve a
better understanding of the meaning of a given FKSI-DRS score
and the implications of a change in that score.
Converting a summary score into a percentage is also consis-
tent with the goal of fundamental measurement. The goal of a
fundamental measurement model is to obtain an estimate of what
the underlying concept (or construct) might look like if we create
a ruler, as a common currency, tomeasure the construct, regardless
of what instrument is used and which patient will use the instru-
ment [13]. Fundamental measurement theory operates within the
principles of the Rasch model, which, based on conditional logis-
tic function, provides estimates of item difﬁculty independent of
the distribution of disease severity and estimates of disease severity
independent of the distribution of item difﬁculty. Converting
derived metric measures into percentages not only is consistent
with the fundamental measurement model but also supports
lucidly and uniformly the standardization of results.
The method of interpretation used in this study was based on
the content of an instrument (content-based interpretation) and
relied on one or more representative items of the instrument to
understand the meaning of the instrument score. This content-
based approach has been applied to enhance the interpretation of
several health assessment scales, such as the short form-36 health
survey (SF-36) [22], the Visual Function Index [21], and the
National Eye Institute Visual Function Questionnaire [11]. The
content-based approach is straightforward for a single-item
instrument but becomes more complex when an instrument
includes multiple items. For instruments that include a number of
items, it often becomes impractical and confusing to use all the
items for an interpretation. Selecting a representative item to
understand the meaning of an instrument score is more practi-
cable and relevant.
The lack of model ﬁt for the blood urine item is not surprising.
As shown in Table 1, four positive response categories (“very
much,” “quite a bit,” “somewhat,” and “a little bit”) to the blood
urine item were either not endorsed or were responded to by only
1% of patients. Categories with low response levels generally do
not provide enough information for an estimation of stable thresh-
old values and are likely to be problematic [13]. The low positive
response to the blood urine item is consistentwith a previous study
where this item was strongly endorsed by neither patients nor
health-care providers during the development of the FKSI [2].
Nevertheless, expert review suggested that the blood urine
symptom should be retained in the ﬁnal instrument [2]. This item,
although relatively rare among patients in our study, can still be
relevant to patients at a more advanced stage of kidney disease
progression when hematuria may become an issue. If a more
diverse sample froma population that included subjectswithmore
advanced renal cell carcinomawas included, it is possible that this
item may have shown more favorable characteristics; more
research is needed here.
This study raises additional considerations, which represent
potential limitations. First, the Rasch model has been criticized as
overly restrictive because it discriminates equally across all items
rather than estimate a discrimination parameter for each item.
This overly restritive limitation is observed in our estimates of the
item-total score correlation. Because the item-total score corre-
lation can be a surrogate for item discrimination, evidence exists
(from Table 1) that the item discriminations are not uniform. The
item “I have blood in urine” in particular has a low item-total
score correlation and, hence, low discrimination. In contrast to
the Rasch model, item discrimination is available in multiparam-
eter logistic models. Second, our study used all available subjects
across a range of ethnic and cultural subpopulations. Because the
ﬁt of the model and its interpretation of the data may differ
between countries (and languages), we suggest that future
research investigate the differential functioning of FKSI-DRS
items on a country-by-country basis with a sufﬁciently large
patient population per country to examine possible country dif-
ferences. Finally, we used data only from day 28, cycle 1, and did
not report the results from other cycles. Nevertheless, although
estimates were not expected to be identical (and were not iden-
tical) for each cycle, they were consistent in direction and mag-
nitude across the cycles. We used day 28, cycle 1 because it
provided the largest and most varied sample size and thereby the
fullest available information.
Conclusions
In summary, application of the Rasch rating scale model to the
FKSI-DRS helps to enrich the meaning of FKSI-DRS summary
scores and provides this scale with additional psychometric
support. The ﬁndings from this study should help to facilitate use
of the FKSI-DRS in future clinical studies and improve awareness
and understanding of the scale among patients, physicans, and
decision-makers. Although the current study focused on the
FKSI-DRS, the same method may be used to validate and
enhance the interpretation of other health assessment scales.
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